Literature DB >> 21281819

Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.

Jong-Wei Hsu1, Sayeda Yasmin-Karim, Michael R King, Joel C Wojciechowski, Deanne Mickelsen, Martha L Blair, Huei-Ju Ting, Wen-Lung Ma, Yi-Fen Lee.   

Abstract

Adhesion of circulating prostate cancer (PCa) cells to the microvascular endothelium is a critical step during cancer metastasis. To study PCa cell rolling and adhesion behavior, we developed a dynamic flow-based microtube system to mimic the microvascular environment. We found that PCa cell rolling capacity is mediated by E-selectin and can be enhanced by stromal cell-derived factor-1 under different wall shear stresses. Using this device, we tested if the chemopreventive agent, vitamin D, could interfere with PCa cell adhesion. We found that 1α,25-dihydroxyvitamin D(3) (1,25-VD), the bioactive form of vitamin D, reduced PCa cell rolling numbers and increased rolling velocities resulting in a significant decreased number of PCa cells adhering to the microtube. The inhibitory effects of 1,25-VD on PCa cell heterotypic adhesion were further confirmed using microvascular endothelial cells in a static condition. Furthermore, we demonstrated that 1,25-VD can increase E-cadherin expression in PCa cells and promote the homotypic cell-cell aggregation, which can then hinder PCa cell adhesion to the endothelium. Blocking E-cadherin with a neutralizing antibody can reverse 1,25-VD-mediated suppression of PCa cell adhesion to the endothelium. Taken together, our data revealed that 1,25-VD promoted PCa cell aggregation by increasing E-cadherin expression, thus interfering with circulating PCa cell adhesion to microvascular endothelial cells and potentially reducing their metastatic potential.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281819      PMCID: PMC3069912          DOI: 10.1016/j.ajpath.2010.10.036

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.

Authors:  V Sung; D Feldman
Journal:  Mol Cell Endocrinol       Date:  2000-06       Impact factor: 4.102

2.  Stromal derived factor-1-induced chemokinesis of cord blood CD34(+) cells (long-term culture-initiating cells) through endothelial cells is mediated by E-selectin.

Authors:  A J Naiyer; D Y Jo; J Ahn; R Mohle; M Peichev; G Lam; R L Silverstein; M A Moore; S Rafii
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

3.  Hemodynamic shear stress and its role in atherosclerosis.

Authors:  A M Malek; S L Alper; S Izumo
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins.

Authors:  Tobias Engl; Borna Relja; Dana Marian; Christa Blumenberg; Iris Müller; Wolf-Dietrich Beecken; Jon Jones; Eva M Ringel; Jürgen Bereiter-Hahn; Dietger Jonas; Roman A Blaheta
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

5.  1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis.

Authors:  Bo-Ying Bao; Jorge Yao; Yi-Fen Lee
Journal:  Carcinogenesis       Date:  2006-04-19       Impact factor: 4.944

Review 6.  Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis.

Authors:  F W Orr; H H Wang
Journal:  Surg Oncol Clin N Am       Date:  2001-04       Impact factor: 3.495

7.  Severe inflammatory defect and reduced viability in CD18 and E-selectin double-mutant mice.

Authors:  S B Forlow; E J White; S C Barlow; S H Feldman; H Lu; G J Bagby; A L Beaudet; D C Bullard; K Ley
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  L-selectin shedding regulates leukocyte recruitment.

Authors:  A Hafezi-Moghadam; K L Thomas; A J Prorock; Y Huo; K Ley
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

9.  Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion.

Authors:  M A Thoreson; P Z Anastasiadis; J M Daniel; R C Ireton; M J Wheelock; K R Johnson; D K Hummingbird; A B Reynolds
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

10.  Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling.

Authors:  H G Pálmer; J M González-Sancho; J Espada; M T Berciano; I Puig; J Baulida; M Quintanilla; A Cano; A G de Herreros; M Lafarga; A Muñoz
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539

View more
  21 in total

1.  Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines.

Authors:  Siddarth Chandrasekaran; Yue Geng; Lisa A DeLouise; Michael R King
Journal:  Biomaterials       Date:  2012-09-17       Impact factor: 12.479

Review 2.  [Prostate cancer prophylaxis by dietary supplements: more than just an illusion?].

Authors:  W Merkle
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

3.  Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.

Authors:  Kathleen Torkko; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Jeannette M Schenk; M Scott Lucia; Ulrike Peters; Adrie van Bokhoven; Ian M Thompson; Marian L Neuhouser
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-26

Review 4.  Modeling prostate cancer in mice: limitations and opportunities.

Authors:  Patrick J Hensley; Natasha Kyprianou
Journal:  J Androl       Date:  2011-06-16

Review 5.  The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃.

Authors:  E Vanoirbeek; A Krishnan; G Eelen; L Verlinden; R Bouillon; D Feldman; A Verstuyf
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-08       Impact factor: 4.690

6.  Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.

Authors:  Irene M Shui; Lorelei A Mucci; Peter Kraft; Rulla M Tamimi; Sara Lindstrom; Kathryn L Penney; Katharina Nimptsch; Bruce W Hollis; Natalie Dupre; Elizabeth A Platz; Meir J Stampfer; Edward Giovannucci
Journal:  J Natl Cancer Inst       Date:  2012-04-12       Impact factor: 13.506

Review 7.  Vitamin D safety and requirements.

Authors:  Francisco J A de Paula; Clifford J Rosen
Journal:  Arch Biochem Biophys       Date:  2011-12-09       Impact factor: 4.013

8.  Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.

Authors:  Jong-Wei Hsu; Iawen Hsu; Defeng Xu; Hiroshi Miyamoto; Liang Liang; Xue-Ru Wu; Chih-Rong Shyr; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

Review 9.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

Review 10.  Relevance of Vitamin D in Melanoma Development, Progression and Therapy.

Authors:  Anna A Brożyna; Robert M Hoffman; Andrzej T Slominski
Journal:  Anticancer Res       Date:  2020-01       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.